Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 232-221-5 | CAS number: 7790-76-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- No data
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- Published data on structurally similar substance from peer reviewed paper. The reliability has been amended in accordance with 'practical guide 6: How to report read-across and categories' which states that the maximum reliability for a read-across study is 2. The study is considered to be adequate and reliable for the purpose of registration under REACH (Regulation (EC) No. 1907/2006). Read across to dicalcium pyrophosphate can be justified on the following basis; Both substances are structurally similar ionic inorganic compounds consisting of calcium cations and pyrophosphate anions and as such the in vivo break-down products are the same.
Data source
Reference
- Reference Type:
- publication
- Title:
- A 90-day subchronic toxicity study of beta-calcium pyrophosphate in rat
- Author:
- Lee JH, Chang B-S, Ryu H-S & Lee C-K
- Year:
- 2 009
- Bibliographic source:
- Drug and Chemical Toxicology, 32(3): 277-282
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: ISO 10993 Biological Evaluation of Medical Devices Part II (1995): test for systemic/6.7 subchronic oral application
- Principles of method if other than guideline:
- Evaluation of toxicity from subchronic oral administration of β-calcium pyrophosphaste to male and female Sprague-Dawley rats.
- GLP compliance:
- not specified
- Limit test:
- yes
Test material
- Reference substance name:
- Dicalcium pyrophosphate
- EC Number:
- 232-221-5
- EC Name:
- Dicalcium pyrophosphate
- Cas Number:
- 7790-76-3
- Molecular formula:
- Ca2O7P2
- IUPAC Name:
- dicalcium (phosphonatooxy)phosphonate
- Reference substance name:
- Beta calcium pyrophosphate
- IUPAC Name:
- Beta calcium pyrophosphate
- Test material form:
- other: aqueous extract of beta calcium pyrophosphate
- Details on test material:
- β-calcium pyrophosphate (β-CPP) was prepared by reacting high-purity Ca2P2O7 (Sigma-Aldrich Co, St Louis, Missouri, USA; 99.99 %;) with CaCO3 (High Purity Chemicals, Sakado, Japan; 99.99 %) in the solid state. Porous β-CPP was prepared by using polyurethane foams with randomly interconnected pores (60 ppi). Polyurethane foams were coated with β-CPP slurry and then burned and sintered at 1,100 to 1,300 °C for 2 hours. The resulting porous β-CPP contained interconnected pores (pore size 300-500 μm) and a porosity of 80 %, which is similar to that of natural spongy bone.
Constituent 1
Constituent 2
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Dae Han Biolink Inc, ChoongChung-BukDo, Korea
- Age at study initiation: 5 weeks
- Weight at study initiation: 182 ± 8 g (treated males); 163 ±7 g (treated females); 183 ± 8 g (control males); 163 ± 6 g (control females)
- Fasting period before study: No
- Housing: metal cages
- Diet (e.g. ad libitum): γ-irradiated (25-40 kGy; Greenpai, Yugookun, Korea) commercial feed (Purina feed for rats; Nestle Purina Pet Care Co, St Louis, USA)
- Water (e.g. ad libitum): autoclaved (121 °C for 15 min)
- Acclimation period: 7 days in individual cages
ENVIRONMENTAL CONDITIONS
- Temperature: 20-24 °C
- Humidity: 45-50 %
- Air changes (per hr): room air turnaround was 12-18 times/hour
- Photoperiod (hrs dark / hrs light): 12 hours light (07:00 to 19:00) and 12 hours dark
IN-LIFE DATES: From: Day minus 7 To: Day 90
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- other: saline
- Details on oral exposure:
- Aqueous extracts for the administration experiments were prepared by dissolving 0.1026 g of β-CPP in 34.2 mL of saline at 70 ± 2 °C for 24 hours.
- Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 90 days
- Frequency of treatment:
- Daily between 10:00 am and 12:00 am
Doses / concentrations
- Remarks:
- Doses / Concentrations:
30 mg/kg bw/d
Basis:
other: nominal in saline
- No. of animals per sex per dose:
- 10 males and 10 females
- Control animals:
- yes, concurrent vehicle
Examinations
- Observations and examinations performed and frequency:
- - Body weights were recorded at baseline and then weekly until scheduled sacrifice 90 days later.
- Average daily consumptions of water and food were determined by weighing and overall mean weekly consumptions during the 90-day treatement period were calculated.
- Clinical observations were made twice daily during the treatment period to detect mortality, morbidity and signs of toxicity.
- An opthalmic examination was conducted on all rats at baseline and towards the end of the treatment period. Both eyes in each rat were examined by focal illumination and indirect opthalmoscopy (ALL PUPIL, Keeler, Windsor, UK) in subdued light after inducing mydriasis. - Sacrifice and pathology:
- - On day 90, all animals were anaethetised with ether, euthanised by exsanguination, weighed, and blood samples were collected from abdominal aorta for haematology and serum biochemistry.
- Each animal was subjected to complete necropsy including external body macroscopic examinations.
- The weights of heart, liver, lung, kidney (both), spleen, adrenal glands (both), brain, thymus, pituitary gland, testes (both) and ovaries (both) were determined.
- Organ-to-body-weight and organ-to-brain-weight ratios were calculated.
- At sacrifice, samples of the tissues and organs listed above, and all gross lesions, were fixed and preserved in 10 % neutral buffered formalin.
- Tissue samples from all animals were further processed for histopathology. The following tissues and organs were sectioned at 2 μm and H&E (haematoxylin and eosin) stained: digestive system (oesophagus, stomach, duodenum, jejunum, ileum, caecum, colon, liver, gall bladder, salivary gland and pancreas); urinary system (kidney and urinary bladder); respiratory system (lung and trachea); cardiovascular system (heart and aorta); haematopoietic system (spleen, thymus, lymph nodes and bone marrow); endocrine system (adrenal, pituitary, thyroid and parathyroid glands); nervous system (brain and spinal cord); muscular skeletal system (skeletal muscle, femur and sternum); male reproductive system (testes, epididymides, prostate and seminal vessel); female reproductive system (ovaries, uterus, mammary glands and vagina), skin, tongue and eyes. - Other examinations:
- - Urine volume and urine colour was assessed by eye.
- Specific gravity (SG), pH, leukocyte esterase, nitrate, protein, glucose, ketone bodies, urobilinogen and bilirubin, and occult blood was evaluated by using urinalysis reagent stripts (Combur-Test M; Roche Diagnostics, Mannheim, Germany) and a urine analyser (GmbH, Roche Diagnostics, Mannheim, Germany) during the 90-day treatment period.
- The following haematological parameters were evaluated: red blood cell count (RBC, white blood cell count (WBC), haemaglobin, hematocrit, mean corpuscular volume (MCV), mean corpuscular haemaglobin (MCH), mean corpuscular haemaglobin concentration (MCHC) and platelet count (using an animal blood counter; Vet ABC, Montpellier, France). Prothrombin times (PTs) and activated partial thromboplastin time (aPTT) were also evaluated. Differential blood cell counts (i.e of lymphocytes, neutrophils, basophils, eosinophils and monocytes) were performed microscopically after Wright-
giemsa staining.
- Clinical chemistry parameters such as total protein, albumin, glucose, total cholesterol, triglyceride (TG), total bilirubin, blood urea nitrogen (BUN), creatinine, alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), Cl, Ca, K and P were evaluated using a chemisty analyser (7070 Automatic Analyser, Hitachi, Japan) using separate plasma samples. - Statistics:
- Mean and statistical deviations were calculated for all quantitative data. If warranted, and based on group size constraints, the test and control groups were compared by using one-way analysis of variance, followed by the Dunnett's multiple comparison test. Homogeneity of variances was tested using Bartlett's test and, when differences were significant (P<0.05), the Kruskal-Wallis test was performed. When those results were significant, the Wilcoxon-Mann-Whitney rank-sum test and the Nemenye-Kruskal-Wallis multiple comparisons were performed. The Chi-square test was used to determine the significances of histopathological changes.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- β-CPP and control group animals gained weight equally over the treatment period (see Table 1, attached)
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- no effects observed
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- no effects observed
- Description (incidence and severity):
- no treatment-related abnormalities in treated or control animals during the test period
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- See Table 2 (attached)
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- - No mortalities occurred during the study, and no clinical signs or behavioural or motor activity changes were observed that could have been attributed to treatment.
- No diet-related effects on feed intake were observed.
- No statistically significant differences in mean body weight gain (see Table 1, attached) or mean feed efficiency were observed between the β-CPP and control groups, or between male and female rats in the two groups.
- No significant differences were observed between β-CPP and control males or females in terms of urinalysis response variables by random sampling.
- Mean serum chloride level in β-CPP-treated males (104 ± 1) was significantly higher (P = 0.026) than in controls (102 ± 2).
- Mean aPTT, cholesterol and AST(GOT) levels in β-CPP females (25.5 ± 3; 102 ± 18 and 133 ± 34 respectively) were significantly lower (P = 0.021, P = 0.049 and P = 0.026 respectively) than in control females (28.1 ± 2.0; 112 ± 11 and 170 ± 21). However, the four parameters were within the normal range in both female subgroups (see Table 2, attached).
- No differences were observed between β-CPP and control groups with respect to other haematologic response and response variables.
- No differences were found between the two study groups or between males and females in these groups with respect to absolute or relative organ weights (see Table 3, attached)
- Microscopic histopathology revealved no evidence of changes that could be attributed to β-CPP treatment. All observed findings were typical for the Sporague-Dawley strain.
Effect levels
- Dose descriptor:
- NOAEL
- Remarks:
- 30 mg/kg bw/d
- Based on:
- act. ingr.
- Sex:
- male/female
- Basis for effect level:
- other: see 'Remark'
- Remarks on result:
- not measured/tested
- Remarks:
- Effect level not specified (migrated information)
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- No adverse effects were detected in male or female rats when β-calcium pyrophosphate was fed orally at 30 mg/kg bw/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.